Operating leverage is now confirmed on a full-year basis
EASYVISTA

Operating leverage is now confirmed on a full-year basis

H2 patterns are similar to H1’s, which showed for the first time a significant positive EBITDA (€2.1m vs €-1.8m in H1 17), confirming the consistency of the business model. EasyVista’s products/marketing/sales assets were strengthened in previous years, which now comforts the growth pace, alongside the EBITDA margin.

EBITDA: €3.9m vs €-0.77m in 2017

As EasyVista runs a fixed cost model, margins grow rapidly after reaching the breakeven point, which was done in 2017. 2018 is the first fully impacted year, with a 10.4% EBITDA margin, vs <0 in FY 17. H1 showed a better margin (11.4%) than in H2 (9.3%), which can be explained by substitution impacts (see our 13 February comment), as well as sustained marketing efforts to capture new markets.

Significant expansion in 2018

France (sales +32%) and the USA (+38% excl. change), the major group’s markets, showed significant market successes, in both the private and public sectors: in France, amongst others, the Department of Human Services, Bank of France, the National Assembly, Plastic Omnium, Sopra Immobilier, Eiffage, Gemalto, CFF; in In the USA, we can mention Des Moines, USA Truck, schools & universities and in Self-Help solution,Carestream Dental.

Many opportunities to seize

The coming years should continue to prove dynamic. EasyVista Edge is based on a global solution to make delivery and support easy to implement, user-friendly and with codeless workflow settings. Customer ROI is strong, and we can contemplate positive trends for the year ahead. We assume a 15-20% organic growth trend.

Booked growth in 2019 is unlikely to reach this organic trend, due to the backlog impact of the substitution in contracting mode, which boosted revenue recognition in 2017 and 2018. Even though, we still expect +10% growth in sales. Management also anticipates an increase in the EBITDA margin (we expect 12% vs 10% in 2018.

No change in 2020 targets and valuation

We confirm our scenario of growth by 2020, where we expect sales of €47m and €8m of EBITDA. Our DCF results in a €49 target price, unchanged.

View all research reports on Easyvista : cliquez-ici

View detailed fundemental analysis on Easyvista : cliquez-ici


The AlphaValue Corporate Services analysts are AlphaValue’s sector specialists. Their robust knowledge of the business models in their sectors enables the rapid generation of incisive, relevant research and advantageous interaction with the management teams.


IMPORTANT DISCLOSURES: © 2018, AlphaValue. All rights reserved. Contract research, paid for by the above corporate entity. Equity research methods and procedures are as applied by AlphaValue. Target prices and opinions are thus exclusively determined by those methods and procedures. All opinions and estimates included herein represent the personal, technical judgment of the analyst as of the date of this report and are subject to change without prior notice. The information contained herein is not intended to be an offer/solicitation to buy or sell any securities and has been compiled from sources believed to be reliable, but while all reasonable care has been taken to ensure that the information contained herein is not untrue or misleading at the time of publication, we make no representation that it is accurate or complete and it should not be relied upon as such. AlphaValue does not accept any liability whatsoever for any direct or consequential loss arising from any use of this report or its contents, including the investment view held in this report.

Related posts